Abstract
Dystrophinopathy is a rare, severe muscle disorder, and nonsense mutations are found in 13% of cases. Ataluren was developed to enable ribosomal readthrough of premature stop codons in nonsense mutation (nm) genetic disorders.
| Original language | English |
|---|---|
| Pages (from-to) | 477-487 |
| Number of pages | 11 |
| Journal | MUSCLE & NERVE |
| Volume | 50 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
All Science Journal Classification (ASJC) codes
- Physiology
- Clinical Neurology
- Cellular and Molecular Neuroscience
- Physiology (medical)
Keywords
- Adolescent
- Child
- Codon
- Dose-Response Relationship
- Double-Blind Method
- Drug
- Duchenne
- Duchenne muscular dystrophy
- Dystrophin
- Humans
- International Cooperation
- Male
- Muscular Dystrophy
- Nonsense
- Outcome Assessment (Health Care)
- Oxadiazoles
- Preschool
- Prospective Studies
- Time Factors
- Walking
- genetic
- nonsense mutation
- orphan
- pediatric
Fingerprint
Dive into the research topics of 'Ataluren treatment of patients with nonsense mutation dystrophinopathy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver